Mamdouh R. Rezk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mamdouh R. Rezk has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
Ezzat M. Abdel-Moety
Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, ET-11562 Cairo, Egypt
6 shared publicationsHayam M. Lotfy
Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr el Aini Street, 11562 Cairo, Egypt; Pharmaceutical Chemistry Department, Faculty of Pharmaceutical Sciences & Pharmaceutical Industries, Future University, 12311 Cairo, Egypt
6 shared publications- Hoda M. Marzouk
Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo 11562, Egypt
6 shared publications Mostafa A. Shehata
Cairo University, Faculty of Pharmacy, Analytical Chemistry Department, Kasr El-Aini St, 11562 Cairo, Egypt
6 shared publicationsAhmed S. Fayed
Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, ET-11562 Cairo, Egypt
5 shared publications- Amr Mohamed Mahmoud
Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo 11562, Egypt
5 shared publications
Latest Publications
- Open Access
- 14 February 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (8) , 11209-11220
Bioequivalence evaluation of two cariprazine hard capsule formulations
Cariprazine, a third-generation antipsychotic, is indicated for schizophrenia and bipolar I disorder. Affordable formulations are essential for improving access and adherence, particularly in resource-limited settings. We aimed to assess the bioequivalence, safety, and tolerability of a newly developed generic hard capsule Vocarzine (1.5 mg) compared to a branded reference product of cariprazine hard capsule (Reagila®) under fasting conditions in healthy adult participants. In a randomized, open-label, single-dose, two-period, two-sequence crossover design, 30 healthy male and female participants received a single oral dose of either the test or reference product, with 4-week washout period. Pharmacokinetics were evaluated using validated LC–MS/MS methods. Bioequivalence was concluded if the 90% confidence intervals (CIs) for the geometric mean ratios (GMRs) of peak plasma concentration (C max ) and area under the concentration–time curve from time zero to 72 h (AUC 0-72h ) fell within 80–125%. Twenty-nine participants completed the study. The GMR (90% CI) for C max was 91.92% (85.07–99.33%) and for AUC 0-72h was 92.85% (88.86–97.02%), both within the bioequivalence acceptance range (80–125%). Both formulations were well tolerated; mild nausea was the most common adverse event, and no serious adverse events were reported. The two hard capsule formulations were bioequivalent, in terms of rate and extent of absorption, with a comparable safety profile, supporting the use of vocarzine as a safe, effective, and potentially cost-saving alternative. Clinical trial number: The ClinicalTrials.gov registration number is NCT07121868, retrospectively registered on August 13, 2025.
- 14 February 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (8) , 11209-11220
Open AccessBioequivalence evaluation of two cariprazine hard capsule formulations
Cariprazine, a third-generation antipsychotic, is indicated for schizophrenia and bipolar I disorder. Affordable formulations are essential for improving access and adherence, particularly in resource-limited settings. We aimed to assess the bioequivalence, safety, and tolerability of a newly developed generic hard capsule Vocarzine (1.5 mg) compared to a branded reference product of cariprazine hard capsule (Reagila®) under fasting conditions in healthy adult participants. In a randomized, open-label, single-dose, two-period, two-sequence crossover design, 30 healthy male and female participants received a single oral dose of either the test or reference product, with 4-week washout period. Pharmacokinetics were evaluated using validated LC–MS/MS methods. Bioequivalence was concluded if the 90% confidence intervals (CIs) for the geometric mean ratios (GMRs) of peak plasma concentration (C max ) and area under the concentration–time curve from time zero to 72 h (AUC 0-72h ) fell within 80–125%. Twenty-nine participants completed the study. The GMR (90% CI) for C max was 91.92% (85.07–99.33%) and for AUC 0-72h was 92.85% (88.86–97.02%), both within the bioequivalence acceptance range (80–125%). Both formulations were well tolerated; mild nausea was the most common adverse event, and no serious adverse events were reported. The two hard capsule formulations were bioequivalent, in terms of rate and extent of absorption, with a comparable safety profile, supporting the use of vocarzine as a safe, effective, and potentially cost-saving alternative. Clinical trial number: The ClinicalTrials.gov registration number is NCT07121868, retrospectively registered on August 13, 2025.
- Open Access
- 26 November 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (5) , 6733-6743
Bioequivalence assessment of imeglimin hydrochloride tablet, a novel glimin-class antidiabetic agent
Purpose: While imeglimin’s, oral antidiabetic agent, efficacy and safety are established in Japanese and Western populations, pharmacokinetic data from Middle Eastern and African cohorts remain limited. This study aimed to evaluate the bioequivalence of test and reference imeglimin formulations under fasting conditions in healthy Egyptian adults. Methods: In a randomized, open-label, two-period, two-sequence crossover trial, healthy male and female adults received a single 500 mg oral dose of either formulation under fasting conditions, separated by a one-week washout. Adverse events (AEs) were assessed via direct questioning, participants’ reporting, vital signs monitoring, and clinical laboratory evaluations. Plasma concentrations were measured up to 72 h post-dose, and pharmacokinetic parameters were derived using non-compartmental analysis. Bioequivalence was concluded if the geometric mean ratios (GMRs) and 90% confidence intervals (CIs) for peak plasma concentration (C max ), area under the concentration–time curve to 72 h (AUC 0-72 ), and to infinity (AUC 0–inf ) were within 80–125%. Results: In 29 healthy participants, all pharmacokinetic endpoints met bioequivalence criteria. GMR (90% CI) for each pharmacokinetic endpoint were: C max 101.75% (94.42–109.64); AUC 0–72 100.66% (94.28–107.46); AUC 0–inf 100.13% (93.77–106.92). The intrasubject variability was low (14–17%). Both formulations were well tolerated, with only mild transient adverse events (headache, abdominal pain) and no serious events. Conclusion: The test formulation of imeglimin was bioequivalent to the reference, with a favorable safety profile. This first pharmacokinetic and bioequivalence study in a Middle Eastern/African population supports regulatory approval and enhances opportunities for affordable access to imeglimin in type 2 diabetes management. Clinical trial number. The ClinicalTrials.gov registration number is NCT07127094, retrospectively registered on August 15, 2025. Graphical
- 26 November 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (5) , 6733-6743
Open AccessBioequivalence assessment of imeglimin hydrochloride tablet, a novel glimin-class antidiabetic agent
Purpose: While imeglimin’s, oral antidiabetic agent, efficacy and safety are established in Japanese and Western populations, pharmacokinetic data from Middle Eastern and African cohorts remain limited. This study aimed to evaluate the bioequivalence of test and reference imeglimin formulations under fasting conditions in healthy Egyptian adults. Methods: In a randomized, open-label, two-period, two-sequence crossover trial, healthy male and female adults received a single 500 mg oral dose of either formulation under fasting conditions, separated by a one-week washout. Adverse events (AEs) were assessed via direct questioning, participants’ reporting, vital signs monitoring, and clinical laboratory evaluations. Plasma concentrations were measured up to 72 h post-dose, and pharmacokinetic parameters were derived using non-compartmental analysis. Bioequivalence was concluded if the geometric mean ratios (GMRs) and 90% confidence intervals (CIs) for peak plasma concentration (C max ), area under the concentration–time curve to 72 h (AUC 0-72 ), and to infinity (AUC 0–inf ) were within 80–125%. Results: In 29 healthy participants, all pharmacokinetic endpoints met bioequivalence criteria. GMR (90% CI) for each pharmacokinetic endpoint were: C max 101.75% (94.42–109.64); AUC 0–72 100.66% (94.28–107.46); AUC 0–inf 100.13% (93.77–106.92). The intrasubject variability was low (14–17%). Both formulations were well tolerated, with only mild transient adverse events (headache, abdominal pain) and no serious events. Conclusion: The test formulation of imeglimin was bioequivalent to the reference, with a favorable safety profile. This first pharmacokinetic and bioequivalence study in a Middle Eastern/African population supports regulatory approval and enhances opportunities for affordable access to imeglimin in type 2 diabetes management. Clinical trial number. The ClinicalTrials.gov registration number is NCT07127094, retrospectively registered on August 15, 2025. Graphical
- Open Access
- 18 November 2025
- Published by Springer Nature in Drugs in R&D
- Vol. 25 (4) , 343-351
Bioequivalence of Two Perampanel Oral Suspension Formulations in Healthy Subjects: A Randomized Crossover Study
Background and Objective Perampanel has been approved for the adjunctive treatment of partial-onset seizures and primary generalized tonic-clonic seizures. The oral suspension formulation benefits patients who have difficulty swallowing tablets. The unavailability of an affordable generic perampanel oral suspension formulation increased the need for a cheaper bioequivalent alternative to the marketed reference product. The study aimed to assess the bioequivalence of two formulations of perampanel oral suspension (0.5 mg/mL) administered under fasting conditions focusing on providing a cost-effective and accessible alternative to current formulations. Methods This was an open-label, two-period, two-sequence, crossover, bioequivalence study conducted under fasting conditions. Healthy subjects were randomized to receive single doses of perampanel oral suspension (12 mg), Lepsiramp and Fycompa® separated by a 6-week washout period. The maximum concentration and area under the concentration–time curve up to 72 h were the primary pharmacokinetic parameters used to assess bioequivalence. Results The geometric mean ratio of test to reference formulations and 90% confidence interval were 109.55 (99.49–120.64) for maximum concentration and 98.15 (90.68–106.23) for the area under the concentration–time curve up to 72 h, which were within the 80–125% bioequivalence range. The adverse events were mild headache and dizziness. Conclusions The two oral suspension formulations were bioequivalent, safe, and well tolerated. This provides a beneficial affordable alternative for patients requiring non-tablet oral formulations. Clinical Trial Registration The ClinicalTrials.gov registration number is NCT06969963, retrospectively registered on 13 May, 2025.
- 18 November 2025
- Published by Springer Nature in Drugs in R&D
- Vol. 25 (4) , 343-351
Open AccessBioequivalence of Two Perampanel Oral Suspension Formulations in Healthy Subjects: A Randomized Crossover Study
Background and Objective Perampanel has been approved for the adjunctive treatment of partial-onset seizures and primary generalized tonic-clonic seizures. The oral suspension formulation benefits patients who have difficulty swallowing tablets. The unavailability of an affordable generic perampanel oral suspension formulation increased the need for a cheaper bioequivalent alternative to the marketed reference product. The study aimed to assess the bioequivalence of two formulations of perampanel oral suspension (0.5 mg/mL) administered under fasting conditions focusing on providing a cost-effective and accessible alternative to current formulations. Methods This was an open-label, two-period, two-sequence, crossover, bioequivalence study conducted under fasting conditions. Healthy subjects were randomized to receive single doses of perampanel oral suspension (12 mg), Lepsiramp and Fycompa® separated by a 6-week washout period. The maximum concentration and area under the concentration–time curve up to 72 h were the primary pharmacokinetic parameters used to assess bioequivalence. Results The geometric mean ratio of test to reference formulations and 90% confidence interval were 109.55 (99.49–120.64) for maximum concentration and 98.15 (90.68–106.23) for the area under the concentration–time curve up to 72 h, which were within the 80–125% bioequivalence range. The adverse events were mild headache and dizziness. Conclusions The two oral suspension formulations were bioequivalent, safe, and well tolerated. This provides a beneficial affordable alternative for patients requiring non-tablet oral formulations. Clinical Trial Registration The ClinicalTrials.gov registration number is NCT06969963, retrospectively registered on 13 May, 2025.
- Open Access
- 29 May 2025
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 15 (23) , 18475-18489
Innovative sensors with selectivity enhancement by molecularly imprinted polymers for the concurrent quantification of donepezil and memantine
This work is overcoming the selectivity issue using the molecularly imprinted polymer (MIP) approach to determine donepezil (DON) and memantine (MEM) in their combined pharmaceutical formulation.
- 29 May 2025
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 15 (23) , 18475-18489
Open AccessInnovative sensors with selectivity enhancement by molecularly imprinted polymers for the concurrent quantification of donepezil and memantine
This work is overcoming the selectivity issue using the molecularly imprinted polymer (MIP) approach to determine donepezil (DON) and memantine (MEM) in their combined pharmaceutical formulation.
- Open Access
- 8 January 2025
- Published by The Royal Society in Royal Society Open Science
- Vol. 12 (1) , 241634
Ultrasensitive turn-off fluorescent sensor for estimation of the new influenza antiviral prodrug baloxavir marboxil in its pharmaceutical formulation
Carbon quantum dots (CQDs) are a recently developed class of fluorescent nanoparticles made from carbon. Co-doping with heteroatoms such as nitrogen and sulfur improved the properties and generated a high quantum yield. In the proposed study, we utilized a simple, cost-effective, single-stage hydrothermal approach to produce extreme photoluminescence co-doped, nitrogen and sulfur, CQDs (N,S-CODs). Thiosemicarbazide was used as a nitrogen and sulfur source, while citric acid was used as a carbon source to produce fluorescent probes. The prepared N,S-CQDs were subjected to extensive characterization. The generated N,S-CQDs yielded strong fluorescence emission at λ em 430.0 nm after excitation at λ ex 360.0 nm, with a relatively high quantum yield of 41.3% utilizing quinine sulfate as a reference fluorescent compound. These N,S-CQDs were applied as fluorescent nanosensors for the ultrasensitive spectrofluorimetric determination of baloxavir marboxil (BXM) directly without pre-derivatization for the first time. BXM effectively quenches the native fluorescence of N,S-CQDs. Considering the optimal conditions, the fluorescence intensity reduction of N,S-CQDs exhibited a ‘turn-off’ response to BXM at concentrations of 10.0–100.0 ng ml −1 , with detection limits of 1.88 ng ml −1 and quantitation limits of 5.69 ng ml −1 , respectively. The proposed method determined BXM successfully in its tablet dosage form and further expanded to confirm the content uniformity of the tablet units in agreement with USP guidelines.
- 8 January 2025
- Published by The Royal Society in Royal Society Open Science
- Vol. 12 (1) , 241634
Open AccessUltrasensitive turn-off fluorescent sensor for estimation of the new influenza antiviral prodrug baloxavir marboxil in its pharmaceutical formulation
Carbon quantum dots (CQDs) are a recently developed class of fluorescent nanoparticles made from carbon. Co-doping with heteroatoms such as nitrogen and sulfur improved the properties and generated a high quantum yield. In the proposed study, we utilized a simple, cost-effective, single-stage hydrothermal approach to produce extreme photoluminescence co-doped, nitrogen and sulfur, CQDs (N,S-CODs). Thiosemicarbazide was used as a nitrogen and sulfur source, while citric acid was used as a carbon source to produce fluorescent probes. The prepared N,S-CQDs were subjected to extensive characterization. The generated N,S-CQDs yielded strong fluorescence emission at λ em 430.0 nm after excitation at λ ex 360.0 nm, with a relatively high quantum yield of 41.3% utilizing quinine sulfate as a reference fluorescent compound. These N,S-CQDs were applied as fluorescent nanosensors for the ultrasensitive spectrofluorimetric determination of baloxavir marboxil (BXM) directly without pre-derivatization for the first time. BXM effectively quenches the native fluorescence of N,S-CQDs. Considering the optimal conditions, the fluorescence intensity reduction of N,S-CQDs exhibited a ‘turn-off’ response to BXM at concentrations of 10.0–100.0 ng ml −1 , with detection limits of 1.88 ng ml −1 and quantitation limits of 5.69 ng ml −1 , respectively. The proposed method determined BXM successfully in its tablet dosage form and further expanded to confirm the content uniformity of the tablet units in agreement with USP guidelines.
- 14 July 2024
- Published by Elsevier in Microchemical Journal
- Vol. 205
Innovative eco-friendly stability-indicating HPLC-PDA method for simultaneous determination of the emerging antiviral drugs against COVID-19 infection molnupiravir and favipiravir; degradation kinetic studies along with LC-MS based structure elucidation
- 14 July 2024
- Published by Elsevier in Microchemical Journal
- Vol. 205
Innovative eco-friendly stability-indicating HPLC-PDA method for simultaneous determination of the emerging antiviral drugs against COVID-19 infection molnupiravir and favipiravir; degradation kinetic studies along with LC-MS based structure elucidation
- 10 May 2024
- Published by Oxford University Press (OUP) in Journal of AOAC INTERNATIONAL
- Vol. 107 (5) , 749-760
Development and Evaluation of Chemometric Models for the Estimation of Sumatriptan in the Presence of Naproxen and a Degradation Product Using UV Spectrophotometry
Background: Chemometrics is a discipline that allows the spectral resolution of drugs in a pharmaceutical formulation along with degradation product and it is an alternative to chromatographic methods. Objective: Sumatriptan (SUM) is co-formulated with naproxen (NAP) and used in acute migraine attacks. SUM, which has physiological importance, has not been subjected to any stability-indicating chemometric approaches yet, so there is a need for an accurate and safe method for the assay of the cited drug in its preparations. The greenness and blueness assessment was applied using different ecological metrics, including the Green Analytical Procedure Index (GAPI), Analytical Greenness Metric (AGREE), Analytical Eco-Scale (AES) and new “blueness” evaluation using the Blue Applicability Grade Index (BAGI) tool. Methods: SUM was determined in pharmaceutical formulation along with NAP and in presence of alkali-induced degradation product with simple and cost-effective multivariate approaches using spectrophotometric data. Three chemometric approaches were applied for the stability-indicating determination of SUM in the presence of NAP. Classical least-squares (CLS), partial least-squares regression (PLS), and principal components regression (PCR)—three multivariate calibration numerical models that were applied to the UV spectra of the mixtures—were used to achieve the best resolution. Results: Sumatriptan was analyzed with mean accuracies for PLS (100.29% ± 1.318) and for PCR (100.60% ± 1.564). The presented methods were compared and validated for their quantitative analyses. Moreover, statistical comparison between the results obtained by the proposed models and the official methods showed no significant differences. Conclusion: The proposed multivariate calibrations were accurate and specific for quantitative analysis of the studied component. PLS is the best method that has the capacity for qualitative analysis of SUM and it is suitable for routine analysis and stability studies of SUM in QC laboratories. Various ecological assessment metrics confirmed the long-standing eco-friendliness of the suggested models. Highlights: Severally overlapped mixtures of SUM along with co-formulated drug NAP and an alkali-induced degradation product were analyzed by three chemometric approaches. The analytical performance of PLS and PCR was compared and validated in terms of root-mean-square error of calibration (RMSEC), SE of prediction, and recoveries. PLS gave the highest predicted concentrations with the lowest RMSEC and root-mean-square error of prediction. The standard addition was applied for accuracy assessment and the results were compared to those of official methods. Proposed models determined SUM in synthetic mixtures and pharmaceutical formulation in QC laboratories and stability studies. Ecological evaluation tools for measuring the environmental friendliness of chemicals were utilized for the first time in the analysis of SUM.
- 10 May 2024
- Published by Oxford University Press (OUP) in Journal of AOAC INTERNATIONAL
- Vol. 107 (5) , 749-760
Development and Evaluation of Chemometric Models for the Estimation of Sumatriptan in the Presence of Naproxen and a Degradation Product Using UV Spectrophotometry
Background: Chemometrics is a discipline that allows the spectral resolution of drugs in a pharmaceutical formulation along with degradation product and it is an alternative to chromatographic methods. Objective: Sumatriptan (SUM) is co-formulated with naproxen (NAP) and used in acute migraine attacks. SUM, which has physiological importance, has not been subjected to any stability-indicating chemometric approaches yet, so there is a need for an accurate and safe method for the assay of the cited drug in its preparations. The greenness and blueness assessment was applied using different ecological metrics, including the Green Analytical Procedure Index (GAPI), Analytical Greenness Metric (AGREE), Analytical Eco-Scale (AES) and new “blueness” evaluation using the Blue Applicability Grade Index (BAGI) tool. Methods: SUM was determined in pharmaceutical formulation along with NAP and in presence of alkali-induced degradation product with simple and cost-effective multivariate approaches using spectrophotometric data. Three chemometric approaches were applied for the stability-indicating determination of SUM in the presence of NAP. Classical least-squares (CLS), partial least-squares regression (PLS), and principal components regression (PCR)—three multivariate calibration numerical models that were applied to the UV spectra of the mixtures—were used to achieve the best resolution. Results: Sumatriptan was analyzed with mean accuracies for PLS (100.29% ± 1.318) and for PCR (100.60% ± 1.564). The presented methods were compared and validated for their quantitative analyses. Moreover, statistical comparison between the results obtained by the proposed models and the official methods showed no significant differences. Conclusion: The proposed multivariate calibrations were accurate and specific for quantitative analysis of the studied component. PLS is the best method that has the capacity for qualitative analysis of SUM and it is suitable for routine analysis and stability studies of SUM in QC laboratories. Various ecological assessment metrics confirmed the long-standing eco-friendliness of the suggested models. Highlights: Severally overlapped mixtures of SUM along with co-formulated drug NAP and an alkali-induced degradation product were analyzed by three chemometric approaches. The analytical performance of PLS and PCR was compared and validated in terms of root-mean-square error of calibration (RMSEC), SE of prediction, and recoveries. PLS gave the highest predicted concentrations with the lowest RMSEC and root-mean-square error of prediction. The standard addition was applied for accuracy assessment and the results were compared to those of official methods. Proposed models determined SUM in synthetic mixtures and pharmaceutical formulation in QC laboratories and stability studies. Ecological evaluation tools for measuring the environmental friendliness of chemicals were utilized for the first time in the analysis of SUM.
- 7 March 2024
- Published by The Electrochemical Society in Journal of the Electrochemical Society
- Vol. 171 (3) , 037510
Novel Carbon Nanotubes/Gold Nanoparticles Modified Carbon Paste Electrochemical Sensor for Antazoline Determination in Aqueous Humor
Antazoline (ANT) is a H1 histamine receptor antagonist having anticholinergic properties used to decrease nasal congestion. It is found in eye drops usually in combination with either tetryzoline (TET) or xylometazoline (XLO). In this work, a novel electrochemical sensor based on carbon paste electrode (CPE) is developed for simple, rapid, sensitive, and selective determination of antazoline in pure form, different pharmaceutical formulations and in presence of aqueous humor. CPE is modified with nanoparticles multiwalled carbon nanotube (MWCNT) composite and further decorated with gold nanoparticles using amperometric electrodeposition technique to attain Au-NP@MWCNT/CPE for enhancing sensor sensitivity. Linearity is divided into two linear segments and found to be 2 × 10–7 − 2 × 10−6 (1st Linear segment) and 2 × 10–6 − 2 × 10−5 (2nd Linear segment) with limit of detection and quantification of 1.77 × 10−7 and 5.37 × 10−7, respectively. High sensitivity, selectivity, and reproducibility of the modified electrode towards determination of antazoline have promoted its applicability in different dosage forms and in rabbit aqueous humor. This method has noticeable potential applications in quality control, pharmacokinetic studies, and routine determination of antazoline drug in binary pharmaceutical formulations.
- 7 March 2024
- Published by The Electrochemical Society in Journal of the Electrochemical Society
- Vol. 171 (3) , 037510
Novel Carbon Nanotubes/Gold Nanoparticles Modified Carbon Paste Electrochemical Sensor for Antazoline Determination in Aqueous Humor
Antazoline (ANT) is a H1 histamine receptor antagonist having anticholinergic properties used to decrease nasal congestion. It is found in eye drops usually in combination with either tetryzoline (TET) or xylometazoline (XLO). In this work, a novel electrochemical sensor based on carbon paste electrode (CPE) is developed for simple, rapid, sensitive, and selective determination of antazoline in pure form, different pharmaceutical formulations and in presence of aqueous humor. CPE is modified with nanoparticles multiwalled carbon nanotube (MWCNT) composite and further decorated with gold nanoparticles using amperometric electrodeposition technique to attain Au-NP@MWCNT/CPE for enhancing sensor sensitivity. Linearity is divided into two linear segments and found to be 2 × 10–7 − 2 × 10−6 (1st Linear segment) and 2 × 10–6 − 2 × 10−5 (2nd Linear segment) with limit of detection and quantification of 1.77 × 10−7 and 5.37 × 10−7, respectively. High sensitivity, selectivity, and reproducibility of the modified electrode towards determination of antazoline have promoted its applicability in different dosage forms and in rabbit aqueous humor. This method has noticeable potential applications in quality control, pharmacokinetic studies, and routine determination of antazoline drug in binary pharmaceutical formulations.